Nephros Overview
Valuation check: NEPH's ROE is 14.51%, below the Healthcare sector average of 22.01%.
Get informed when a big investor buys or sells
+ Follow14.51%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for NEPH is 14.51%. That is below the Healthcare sector average of 22.01%. Investors often review this figure alongside Nephros's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, NEPH currently prints 14.51% for ROE, while the sector average sits near 22.01%. That is roughly 34.1% below the sector mean. Large gaps often invite a closer look at Nephros's growth, margins, and balance sheet.
Return on Equity shows how effectively Nephros converts resources into returns. At 14.51%, NEPH may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting NEPH's ROE (14.51%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Nephros's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
